La Jolla Pharmaceutical Company (NASDAQ:LJPC) recovered 102.59% of its value since hitting low of $5.01. The recent move of -4.43% drop pushed the stock to close at $10.15 when trading ended on 6/11/2019. At a recent session, the prices were hovering between $10 and $10.88. This company shares are 87.19% off its target price of $19 and the current market capitalization stands at $219.04M. The recent change has given its price a 43.97% lead over SMA 50 and -73.56% deficit over its 52-week high. The stock witnessed 54.02% gains, 45% gains and -26.5% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found LJPC’s volatility during a week at 35.27% and during a month it has been found around 13.46%.La Jolla Pharmaceutical Company (LJPC) Top Holders
Institutional investors currently hold around $270 million or 81% in LJPC stock. Look at its top three institutional owners: Tang Capital Management Llc owns $52.45 million in La Jolla Pharmaceutical Company, which represents roughly 23.95% of the company’s market cap and approximately 19.43% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 4,061,425 shares of the stock are valued at $43.13 million. The third largest holder is Broadfin Capital, Llc, which currently holds $21.19 million worth of this stock and that ownership represents nearly 9.67% of its market capitalization.
At the end of March reporting period, 44 institutional holders increased their position in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by some 6,936,748 shares, 40 decreased positions by 12,786,547 and 20 held positions by 5,704,982. That puts total institutional holdings at 25,428,277 shares, according to SEC filings. The stock grabbed 22 new institutional investments totaling 2,970,862 shares while 22 institutional investors sold out their entire positions totaling 10,303,625 shares.La Jolla Pharmaceutical Company (NASDAQ:LJPC) Insider Trades
Multiple company employees have indulged in significant insider trading. La Jolla Pharmaceutical Company disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Medical Officer Chawla Lakhmir S has acquired 3,000 shares of La Jolla Pharmaceutical Company (LJPC) in the trading session dated Jan. 30, 2019. These shares are worth $16,680 and were traded at $5.56 each. The SEC filing shows that Rolke James performed a purchase of 1,600 shares. The Chief Scientific Officer added these shares by way of transaction on Jan. 09, 2019. The company’s shares were assimilated at $6.09 per share worth to an investment of some $9,744 to the account of Rolke James.
COO, CARVER JENNIFER, purchased 5,000 common shares of La Jolla Pharmaceutical Company (LJPC) in the open market. In a transaction dated Jan. 09, 2019, the shares were bought at an average price of $6.17, giving away a sum of $30,850. After this purchase, 12,116 common shares of LJPC are directly owned by the insider, with total stake valued at $122,977.
In the transaction dated Jan. 09, 2019, a great number of shares acquired came courtesy the Director, 10% Owner; TANG KEVIN C added a total of 1,300,000 shares at an average price of $5.37, amounting to approximately $6,981,000. The insider now directly owns 4,938,893 shares worth $50,129,764.
Several analysts have released their opinion on La Jolla Pharmaceutical Company (NASDAQ:LJPC), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.25 average brokerage recommendation [T1].